The pros and the cons of mTOR inhibitors in kidney transplantation

Expert Review of Clinical Immunology

Volumn 10, Issue 2, 2014, Pages 295-305

  Ponticelli, Claudio ^a  

^a Pancreatic Surgery Section   (Italy)

Author keywords

everolimus; kidney transplantation; mTOR; proliferation signal inhibitor; rejection; sirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTERY INTIMA PROLIFERATION; CANCER RISK; CELL PROLIFERATION; CHEMICAL STRUCTURE; CYTOMEGALOVIRUS; EDEMA; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; ORGAN TRANSPLANTATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; VIRUS REPLICATION;

ANIMALS; CALCINEURIN; GRAFT REJECTION; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; THROMBOCYTOPENIA; TOR SERINE-THREONINE KINASES;

EID: 84893092734     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.872562     Document Type: Review

References (86)

1. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:433-9
2. Wullschleger S, Loewith R, Hall M. TOR signaling in growth and metabolism. Cell 2006;124:471-84
3. Ponticelli C. The mechanisms of acute rejection revisited. J Nephrol 2012;25:150-8
4. Macedo C, Turquist H, Metes D, Thomson AW. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 2012;1:1-16
5. Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine formulations on everolimus. Transplant Proc 2006;38: 3456-8
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22
7. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 dependent pathways. Nat Med 2004;10:594-601
8. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002;8: 128-35
9. Ponticelli C. Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression. Nephrol Dial Transplant 2011;26:1769-75
10. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003;76: 597-602
11. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukaemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-8
12. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80: 883-9
13. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39
14. Johnson RA, Wang X, Ma XL, et al. Human cytomegalovirus up-regulates the phosphatidylinositol-3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits viral replication and virus-induced signalling. J Virol 2001;75:6022-32
15. Smith MS, Bentz GL, Smith PM, et al. HCMV activates PI(3)K monocytes and promotes monocyte motility and transendothelial migration in a dose-dependent manner. J Leukoc Biol 2004;76:65-76
16. Kudchodkar SB, Del Prete GQ, Maguire TG, Alwine JC. AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection. J Virol 2007;81: 3649-51
17. Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant 2012;12: 1458-68
18. Havenith SH, Yong SL, van Donselaar-van der Pant KA, et al. Everolimus-Treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolatetreated patients. Transplantation 2013;95: 184-91
19. Furukawa S, Wei L, Krams SM, et al. PI3Kd inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV) + B cell lymphomas. Am J Transplant 2013;13: 2035-43
20. Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: Toward a new therapy for BK virus infection. Transplantation 2010;90: 1450-7
21. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-Analysis of randomized trials. Transplantation 2006;81:1234-48
22. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011;11: 2453-62
23. Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppressioñ A systematic review and meta-Analysis. Transplantation 2012;94:1208-17
24. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009;87:1019-26
25. Zaltzman JS, Prasad R, Chun K, Jothy S. Resolution of renal allograft-Associated posttransplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 2005;20:1748-51
26. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi sarcoma in renal transplant recpients. N Engl J Med 2005;352:1317-23
27. Martin KA, Rzuicidlo EM, Merenick BL. et al. The mTOR/p70S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Cell Physiol 2004;286:C507-17
28. Schrijvers DM, De Meyer GR, Martinet W. Autophagy in atherosclerosis: A potential drug target for plaque stabilization. Arterioscler Thromb Vasc Biol 2011;31: 2787-91
29. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-Transplant recipients. N Engl J Med 2003;349:847-58
30. Morrissett JD, Abdel-Fattah G, Hogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism. J Lipid Res 2002;43:1170-80
31. Hoogeveen R, Ballantyne CM, Pownall HJ. Effects of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001;72:1244-50
32. Deters S, Kirchner G, Koal T, et al. Everolimus/cyclosporine interactions on bile and biliary excretion of bile salts cholesterol in rats. Dig Dis Sci 2004;49:30-7
33. Lepre F, Rigby R, Hawley C, et al. A double blind controlled trial for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant 1999;13:520-6
34. Knopp RM. Treatment of lipid disorders. N Engl J Med 1999;341:498-511
35. Asberg A. Interactions between cyclosporine and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 2003;663:367-78
36. Broeders N, Knoop C, Antoine M, et al. Fibrate-induce increase in urea and creatinine: Is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15: 1993-9
37. Fishbane S, Cohen DJ, Coyne DW, et al. Posttransplant anemia: The role of sirolimus. Kidney Int 2009;76:376-82
38. Diekmann F, Rovira J, Diaz-Ricart M, et al. mTOR inhibition and erythropoiesis: Microcytosis or anaemiä Nephrol Dial Transplant 2012;27:537-41
39. Friend P, Russ G, Oberbauer R, et al. Incidence of anemia in sirolimus-Treated renal transplant recipients: The importance of preserving renal function. Transpl Int 2007;20:754-60
40. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011;377:837-47
41. Minetti EE. Lymphocele after renal transplantation, a medical complication. J Nephrol 2011;24:707-16
42. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil. cyclosporine, azathioprine, and steroids on wound healing in 513 kidney transplant recipients. Transplantation 2003;76:1729-34
43. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009;88:69-76
44. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications. Transplantation 2004;78:264-8
45. Ponticelli C, Salvadori M, Scolari MP, et al. Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study. Transplantation 2011;91:e72-3
46. Van Gelder T, Ter Meulen CG, Hené R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75:788-91
47. Garrigue V, Canet S, Dereure O, et al. Oral ulcerations in a renal transplant recipient: A mycophenolate mofetil-induced complicatioñ Transplantation 2001;72: 968-9
48. Johnson RW. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002;11:603-7
49. Molina MG, Diekmann F, Burgos D, et al. Sympathetic dystrophy associated with sirolimus therapy. Transplantation 2008;85: 290-2
50. Habib A, Karmali V, Polavarapu R, et al. Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-A activation and disruption of the p120-vascular endothelial cadherin interaction. Arterioscler Thromb Vasc Biol 2013;33:2425-31
51. Pham PT, Pham PC, Danovitch G, et al. Sirolimus-Associated pulmonary toxicity. Transplantation 2004;77:1215-80
52. Errasti P, Izquierdo D, Martín P, et al. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: A single-center experience. Transplant Proc 2010;42:3053-4
53. Robson M, Cote I, Abbs I, et al. Thrombotic microangiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage ? Am J Transplant 2003;3:324-7
54. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol 2007;67:335-40
55. Oyen O, Strøm EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/ hemolytic uremic syndrome. Am J Transplant 2006;6:412-18
56. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int 2012;25: 909-17
57. Sánchez-Fructuoso AI, Ruiz JC, Calvo N, et al. Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors. Transplantation 2012;93:398-405
58. Wiseman AC, McCague K, Kim Y, et al. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant 2013;13:442-9
59. Diekmann F, Andrés A, Oppenheimer F. mTOR inhibitor-Associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 2012;26:27-9
60. Liew A, Chiang GS, Vathsala A. Factors associated with proteinuria in renal transplant recipients treated with sirolimus. Transpl Int 2009;22:313-22
61. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006;21:488-93
62. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706
63. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-Associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006;2:429
64. Franz S, Regeniter A, Hopfer H, et al. Tubular toxicity in sirolimus-And cyclosporine-based transplant immunosuppression strategies: An ancillary study from a randomized controlled trial. Am J Kidney Dis 2010;55:33
65. Vollenbröker B, George B, Wolfgart M, et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009;296:F418
66. Letavernier E, Bruneval P, Vandermeersch S, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009;24:630
67. Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: Evidence for a dose-dependent effect on slit diaphragm-Associated proteins. Transplantation 2011;91:997-1004
68. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356(9225): 194-202
69. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78:1532-40
70. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52
71. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72(5):777-86
72. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004;4:953-61
73. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011;11:1665-75
74. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-7
75. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11: 1633-44
76. Lebranchu Y, Snanoudj R, Toupance O, et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: The SPIESSER study. Am J Transplant 2012;12: 1801-10
77. Flechner SM, Gurkan A, Hartmann A, et al. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation 2013;95:1233-41
78. Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012;12:1528-40
79. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12:1192-8
80. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42
81. Lorber M, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplant recipients based on the exposure-efficacy and safety modelling of 12-month data. Clin Transplant 2005;45-52
82. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-Transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004;78:1332-40
83. Montagnino G, Sandrini S, Iorio B, et al. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008;23:707-14
84. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-Transplant recipients. Am J Transplant 2010;10: 1401-13
85. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 2009;88: 1194-202
86. Peddi VR, Wiseman A, Chavin K, Slakey D. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando) 2013;27:97